Cytokinetics (CYTK) surged 17% after positive Phase 3 trial results for aficamten, showing clinically meaningful improvement in patients with which a form of heart disease that affects the heart muscle.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
